THALES/TELIT-CINTERION
27.2.2024 09:01:30 CET | Business Wire | Press release
Telit Cinterion IoT modules featuring Thales Instant Connect can be remotely activated for cellular connectivity at the time of device installation or during in-field operation. This streamlines IoT deployments as it simplifies supply chain, device installation and maintenance, helping to keep IoT devices connected anywhere, and at all times. Aidon, a leader in smart metering solutions, is the first to benefit from this partnership and solution, deploying IoT modules and initial connectivity from a single vendor, Telit Cinterion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240227054738/en/
credit > sergray
By integrating Thales technology into Telit Cinterion modules, enterprises can enjoy instant out-of-the-box connectivity activation irrespective of the grid of available mobile networks. The collaboration between the two companies on this innovative solution enables them to get their IoT connected products in the market quickly, allowing them to reap the benefits of digital transformation that is at the core of the IoT promise.
The way the solution works is that, at the end of device production or when it is deployed in the field, the Telit Cinterion module uses the initial connectivity provided by Thales Instant Connect, to download the target local connectivity from the network operators selected by the IoT service provider. This allows device manufacturers and service providers to postpone selecting a connectivity provider until after the device is manufactured and throughout the deployment process. It can also be used during in-field operation, enabling deployed devices to stay connected throughout unexpected cellular network outages. This flexibility is particularly beneficial in situations where the devices are deployed across different regions or countries, as it allows for seamless integration with local network operators.
“Helping our enterprise customers to quickly launch and monetize IoT is our mission at Telit Cinterion. Adding the Thales eSIM to our modules in combination with our SIM provisioning and global MVNO services to streamline the final connectivity provider selection is a game changer in the industry. This powerful solution delivers unparalleled adaptability to changing circumstances and simplifies supply chain and logistics because it is based on a single eSIM with Thales Instant Connect, which can be shipped anywhere in the world,” said Manish Watwani, Chief Marketing and Product Officer at Telit Cinterion.
“The IoT eSIM solution is an important innovation, ensuring production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs. The solution provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models,” said Petri Ounila, Director, IoT Devices, Aidon.
“Thales aims to support IoT adopters and streamline device deployment with our eSIM with initial connectivity via Thales Instant Connect service. This simplifies and accelerates large scale IoT deployments for device makers, benefiting all stakeholders in the value chain. Thales is pleased to work with Telit Cinterion to support its success in cellular connectivity and speed up device deployment,” said Guillaume Lafaix, Senior Vice President Mobile Connectivity Solutions at Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
_______________________________
1 Excluding Transport business, which is being divested
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227054738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
